Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZIO-201-T and doxorubicin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single arm | EXPERIMENTAL | Once the maximum tolerated dose (MTD) is determined, an expanded cohort of 20 subjects with advanced, ifosfamide and doxorubicin naive soft-tissue sarcoma subjects will be dosed at the MTD and evaluated for efficacy. |
| Name | Type | Description |
|---|---|---|
| ZIO-201-T and doxorubicin | DRUG | ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm. |
Inclusion Criteria: * Age ≥18 years * Histological or cytological documentation of cancer * Measurable disease * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 * Ifosfamide and doxorubicin naïve * Life expectancy of at least 12 weeks * Adequate bone marrow, liver, and re...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ZIO-201-T and doxorubicin is an investigational combination therapy being studied for the treatment of advanced cancer. It is a small molecule modality in Phase 1 clinical development. The combination is intended for patients with advanced solid tumors, as evaluated in a clinical trial conducted in the United States.
ZIO-201-T and doxorubicin is being developed by Alaunos Therapeutics, Inc., a biopharmaceutical company. Alaunos Therapeutics is publicly traded under the ticker symbol TCRT. The company is conducting clinical research to evaluate this combination therapy for advanced cancer.
ZIO-201-T and doxorubicin is in Phase 1 clinical development. It is an investigational combination therapy and has not been approved by regulatory authorities. The Phase 1 study has been completed, and the drug remains under clinical investigation for advanced cancer.
ZIO-201-T and doxorubicin has one completed clinical trial, identified as NCT00608803. This Phase 1 study evaluated the combination in 30 participants with advanced cancer. The trial was conducted in the United States and enrolled adults aged 18 years and older.
ZIO-201-T and doxorubicin is a combination therapy that includes doxorubicin, but it is not the same as doxorubicin alone. The investigational treatment combines ZIO-201-T with doxorubicin, and the clinical trial was designed to study this specific combination in patients with advanced cancer.